Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Although Tesomet received an Orphan Drug designation from the FDA in 2021, its development was discontinued in 2022 due to funding constraints
Patients Inadequately Controlled on Basal Insulin GetGoal-L-Asia randomised 311 patients with long-duration diabetes (mean 13.9 years) who were inadequately controlled on basal insulin to lixisenatide 20 g OD ( n = 154), or placebo ( n = 157) for 24 weeks [14]
FrstermannUXiaNLiH
:max_bytes(150000):strip_icc()/health-GettyImages-1498826563-72ccaac18ecf41e49988eccfc823270f.jpg)
Accepts insurance and provides insurance assistance
It would be great to undertake studies with the newer dual agonists and polyagonists also in rare obesity syndromes such as AS, Prader-Willi syndrome, and Bardet-Biedl syndrome (just to name a few) as the clinical need for effective obesity/hyperphagia therapies in these patients is especially high, says Scherer
US$ 21.27
US$ 23.80
US$ 25.80
US$ 27.74
US$ 22.53
US$ 27.46
US$ 20.74
US$ 27.42
US$ 27.42
US$ 24.00
